Uric acid Inhibitors
1 drugsAbout Uric acid
Uric acid is a naturally occurring compound in the body involved in metabolic processes. Imbalances in uric acid production or excretion can lead to health issues.
Uric acid has emerged as a therapeutic target for certain metabolic disorders. Currently, there is no genetic evidence data available linking uric acid to specific disease outcomes.
ELITEK (Sanofi) is the only FDA-approved drug targeting uric acid, approved in 2002. It is a biologic (other) modality with 3 indications.
Top Uric acid Drugs
Sanofi is the only company with an approved drug targeting uric acid.
The lack of competition suggests a high barrier to entry or an untapped market opportunity.
Uric acid Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Uric acid, using enzyme modality.
Exploring alternative modalities like small molecules could diversify the therapeutic options.
Uric acid Clinical Trials 8 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Uric acid. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 2 | 2 | 0 | 0 | 100% |
| Phase 2 | 4 | 3 | 1 | 0 | 75% |
| Phase 4 | 2 | 2 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Uric acid Drug Approval Timeline (2002 - 2002)
The first and only drug was approved in 2002.
The long period since the last approval indicates a potential for innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 6 (1 company)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Uric acid. A trial counts if an approved drug acting on Uric acid is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.